United Therapeutics CEO Exercises and Sells $4.99M in Stock Options
UNITED THERAPEUTICS Corp
Subscribe to track UTHR
Premium users can add ticker alerts and receive realtime notification updates.
Filing Summary
United Therapeutics CEO Exercises and Sells $4.99M in Stock Options
Company: UNITED THERAPEUTICS Corp (UTHR) Form: 4 | Filed: 2026-03-23 Significance: Low (Routine 10b5-1 Plan)
Insider: ROTHBLATT MARTINE A Title: Chairperson & CEO | Relationship: Officer/Director
Transaction Details: • Action: Option Exercise & Immediate Sale • Shares: 9,500 • Sale Price: ~$524.99 (Weighted Avg) • Total Value: ~$4,987,376 • Exercise Price: $146.03 • Owned After: 40,513 (Direct)
Key Insight: CEO Rothblatt exercised options expiring in 2027 and sold the resulting shares pursuant to a 10b5-1 trading plan adopted in Nov 2025. While the dollar value is high ($5M), it represents just 0.02% of the company's market cap.
Market Context: Transaction represents <0.1% of shares outstanding for this $23B biotech company.
Comprehensive Analysis
SEC Filing Analysis: UNITED THERAPEUTICS Corp (UTHR)
Executive Summary
- Trading Significance: Low
- Key Takeaway: CEO executes routine exercise-and-sell of 9,500 options via pre-arranged 10b5-1 plan.
- Market Impact: Neutral; transaction volume is negligible relative to market cap.
Company Information
| Field | Value |
|---|---|
| Company | UNITED THERAPEUTICS Corp |
| Ticker Symbol | UTHR |
| CIK | 0001082554 |
| Industry | Pharmaceutical Preparations |
Insider Information
| Field | Value |
|---|---|
| Name | ROTHBLATT MARTINE A |
| CIK | 0001106578 |
| Title/Position | Chairperson & CEO |
| Relationship | Director & Officer |
Transaction Details
| Field | Value |
|---|---|
| Form Type | 4 |
| Transaction Date | 2026-03-20 |
| Transaction Code | M (Exercise) & S (Sale) |
| Security Type | Common Stock |
| Shares Involved | 9,500 |
| Avg Sale Price | ~$524.99 |
| Total Sale Value | ~$4,987,376 |
| Shares Owned After | 40,513 (Direct) |
| Ownership Type | Direct & Indirect (Trusts) |
Financial Impact Assessment
Transaction Materiality
| Metric | Value |
|---|---|
| Transaction Value | $4,987,376 |
| % of Market Cap | 0.02% |
| Shares Transacted | 9,500 |
| % of Shares Outstanding | 0.02% |
| Materiality Assessment | Low |
Impact Evaluation
- Market Cap Context: For a Large Cap company ($23.07B), a $5M transaction is routine operational noise.
- Ownership Concentration: The insider retains significant indirect ownership via trusts (approx. 640,000+ shares), making this sale a small fraction of total holdings.
- Dilution Impact: The exercise of 9,500 options adds 0.02% to the float, which is negligible.
- Transaction Significance: The transaction falls well below the 0.1% threshold for market cap significance.
Market Impact Analysis
Stock Impact Prediction
- Direction: Neutral
- Reasoning: The sale was conducted under a 10b5-1 plan adopted months prior (Nov 2025). This indicates planned liquidity/compensation realization rather than a reaction to current market conditions.
Volume & Sentiment
- Expected Volume Impact: None. 9,500 shares is likely a fraction of daily average volume.
- Sentiment Indicator: Neutral. Executive compensation realization is standard in the biotech sector.
Additional Context
Transaction Notes
- Special Circumstances: The filing explicitly notes a 10b5-1 trading plan adopted on November 7, 2025. The plan continues until Dec 2026 or the exercise of ~1.7M options.
- Profit Taking: The options were exercised at $146.03 and sold at ~$525, generating significant realized gains for the insider.
Get Real-Time Alerts
Join our community to receive instant notifications when high-significance filings are published
Important Disclaimer
This content is drawn from public SEC filings and may contain errors. It is for informational purposes only and is not investment, legal, or tax advice.
Nothing here is a recommendation to buy, sell, or hold any security. Do your own due diligence.